David Gurwitz

List of Publications by Citations

Source: https://exaly.com/author-pdf/6875553/david-gurwitz-publications-by-citations.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202 papers	6,858 citations	43 h-index	77 g-index
247 ext. papers	7,684 ext. citations	9 avg, IF	6.91 L-index

#	Paper	IF	Citations
202	A human genome diversity cell line panel. *Science*, **2002**, 296, 261-2	33.3	742
201	Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Development Research*, **2020**, 81, 537-540	5.1	513
200	The genome-wide structure of the Jewish people. *Nature*, **2010**, 466, 238-42	50.4	295
199	Thrombin modulates and reverses neuroblastoma neurite outgrowth. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 3440-4	11.5	295
198	Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. *Journal of Neurochemistry*, **1990**, 54, 1735-43	6	198
197	Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. *Annals of Human Genetics*, **2009**, 73, 335-45	2.2	181
196	Interleukin-6 attenuation of scopolamine-induced amnesia: plausible involvement of cholinergic neuronal survival. *NeuroReport*, **1997**, 8, i-ii	1.7	123
195	Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. *Biochemical and Biophysical Research Communications*, **2002**, 295, 102-6	3.4	122
194	Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 8284-8	11.5	121
193	The matrilineal ancestry of Ashkenazi Jewry: portrait of a recent founder event. *American Journal of Human Genetics*, **2006**, 78, 487-97	11	120
192	Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. *European Journal of Pharmacology*, **1994**, 267, 21-31		115
191	Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. *Journal of Neurochemistry*, **1996**, 66, 877-80	6	111
190	Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. *Pharmacogenomics*, **2006** , 7, 783-92	2.6	105
189	From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. *Pharmacogenomics*, **2004**, 5, 571-9	2.6	101
188	Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. *Pharmacogenomics Journal*, **2005**, 5, 221-5	3.5	100
187	A global view of the OCA2-HERC2 region and pigmentation. *Human Genetics*, **2012**, 131, 683-96	6.3	86
186	Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. *Trends in Pharmacological Sciences*, **2003**, 24, 122-5	13.2	85

185	Muscarinic receptor binding in mouse brain: regulation by guanine nucleotides. *Biochemical and Biophysical Research Communications*, **1980**, 94, 487-92	3.4	84
184	MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population. *European Journal of Human Genetics*, **2004**, 12, 355-64	5.3	80
183	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. *Pharmacogenomics*, **2007**, 8, 29-39	2.6	78
182	Counting the founders: the matrilineal genetic ancestry of the Jewish Diaspora. *PLoS ONE*, **2008**, 3, e2062	3.7	77
181	Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition. *Journal of Cellular Physiology*, **1990**, 142, 155-62	7	77
180	Research ethics. Children and population biobanks. *Science*, **2009**, 325, 818-9	33.3	73
179	The EU-ADR corpus: annotated drugs, diseases, targets, and their relationships. *Journal of Biomedical Informatics*, **2012**, 45, 879-84	10.2	68
178	Five novel loci for inherited hearing loss mapped by SNP-based homozygosity profiles in Palestinian families. *European Journal of Human Genetics*, **2010**, 18, 407-13	5.3	68
177	Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. *Journal of Affective Disorders*, **2012**, 136, 99-103	6.6	60
176	Single nucleotide polymorphism of the human high affinity choline transporter alters transport rate. *Journal of Biological Chemistry*, **2002**, 277, 45315-22	5.4	60
175	Agonist-specific reverse regulation of muscarinic receptors by transition metal ions and guanine nucleotides. *Biochemical and Biophysical Research Communications*, **1980**, 96, 1296-304	3.4	60
174	(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. *Journal of Pharmacology and Experimental Therapeutics*, **1991**, 257, 392-403	4.7	57
173	Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. *Pharmacogenomics*, **2011**, 12, 171-84	2.6	55
172	Structure-activity studies of the thrombin receptor activating peptide. *Biochemical and Biophysical Research Communications*, **1992**, 188, 604-10	3.4	55
171	Personal genomics services: whose genomes?. *European Journal of Human Genetics*, **2009**, 17, 883-9	5.3	54
170	M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. *Annals of the New York Academy of Sciences*, **1996**, 777, 189-96	6.5	54
169	Agonist and antagonist binding to rat brain muscarinic receptors: influence of aging. *Neurobiology of Aging*, **1987**, 8, 115-22	5.6	54
168	SIRT1, miR-132 and miR-212 link human longevity to Alzheimer's Disease. *Scientific Reports*, **2018**, 8, 8465	4.9	54

167	Effects of age and sex on recovery from COVID-19: Analysis of 5769 Israeli patients. *Journal of Infection*, **2020**, 81, e102-e103	18.9	53
166	Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. *Pharmacogenomics*, **2012**, 13, 1129-39	2.6	52
165	The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. *European Journal of Human Genetics*, **2015**, 23, 1116-23	5.3	49
164	Proteolytic regulation of neurite outgrowth from neuroblastoma cells by thrombin and protease nexin-1. *Journal of Cellular Biochemistry*, **1989**, 39, 55-64	4.7	47
163	Dual pathways in muscarinic receptor stimulation of phosphoinositide hydrolysis. *Biochemistry*, **1987**, 26, 633-8	3.2	47
162	Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. *Translational Psychiatry*, **2013**, 3, e313	8.6	46
161	Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. *Biochemical and Biophysical Research Communications*, **1994**, 203, 652-8	3.4	44
160	Pharmacogenetics in Europe: barriers and opportunities. *Public Health Genomics*, **2009**, 12, 134-41	1.9	43
159	The distribution and most recent common ancestor of the 17q21 inversion in humans. *American Journal of Human Genetics*, **2010**, 86, 161-71	11	42
158	A call for the creation of personalized medicine databases. *Nature Reviews Drug Discovery*, **2006**, 5, 23-6	64.1	38
157	Increased thrombin inhibition in experimental autoimmune encephalomyelitis. *Journal of Neuroscience Research*, **2005**, 79, 351-9	4.4	37
156	Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. *European Journal of Human Genetics*, **2009**, 17, 991-8	5.3	36
155	Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. *Pharmacogenomics*, **2010**, 11, 327-40	2.6	35
154	Pharmacogenetics education in British medical schools. *Genomic Medicine*, **2008**, 2, 101-5		35
153	Ancestry inference of 96 population samples using microhaplotypes. *International Journal of Legal Medicine*, **2018**, 132, 703-711	3.1	34
152	Central muscarinic receptor degeneration following 6-hydroxydopamine lesion in mice. *Life Sciences*, **1980**, 26, 79-84	6.8	34
151	NGF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating. *Journal of Cellular Biochemistry*, **1998**, 70, 425-32	4.7	33
150	NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. *Biochemical and Biophysical Research Communications*, **1995**, 213, 15-23	3.4	33

149	CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. *Pharmacogenomics*, **2009**, 10, 685-99	2.6	32
148	High affinity binding of [3H]acetylcholine to muscarinic receptors. Regional distribution and modulation by guanine nucleotides. *Molecular Pharmacology*, **1985**, 28, 297-305	4.3	32
147	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. *Pharmacogenomics*, **2019**, 20, 643-657	2.6	31
146	Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 1045-1050	11.5	30
145	Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. *Pharmacogenomics Journal*, **2017**, 17, 386-392	3.5	30
144	Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 328, 699-707	4.7	30
143	Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. *Life Sciences*, **2005**, 78, 107-11	6.8	30
142	Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block. *Brain*, **2008**, 131, 1113-22	11.2	29
141	Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. *European Neuropsychopharmacology*, **2004**, 14, 237-43	1.2	28
140	(3-amyloid vasoactivity in Alzheimer's disease. *Lancet, The*, **1996**, 347, 1492-1493	40	28
139	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. *Journal of Molecular Neuroscience*, **2015**, 56, 681-7	3.3	27
138	Personalized medicine: decades away?. *Pharmacogenomics*, **2006**, 7, 237-41	2.6	26
137	Selective signaling via unique M1 muscarinic agonists. *Annals of the New York Academy of Sciences*, **1993**, 695, 300-3	6.5	26
136	Induced interconversion of agonist affinity states in muscarinic receptor from mice brain: effects of temperature and sugars. *Biochemical and Biophysical Research Communications*, **1980**, 94, 493-500	3.4	26
135	Neuronal cell adhesion genes and antidepressant response in three independent samples. *Pharmacogenomics Journal*, **2015**, 15, 538-48	3.5	25
134	Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. *American Journal of Cardiovascular Drugs*, **2001**, 1, 353-61	4	25
133	Quantitative measurements of mouse brain thrombin-like and thrombin inhibition activities. *NeuroReport*, **2001**, 12, 2347-51	1.7	25
132	Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. *Immunobiology*, **2005**, 210, 781-8	3.4	24

131	Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study. *Molecular Psychiatry*, **2021**, 26, 1619-1633	15.1	24
130	Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates. *FASEB Journal*, **2020**, 34, 14160-14165	0.9	23
129	Identification of signaling pathways associated with cancer protection in Laron syndrome. *Endocrine-Related Cancer*, **2016**, 23, 399-410	5.7	23
128	Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. *Molecular Diagnosis and Therapy*, **2004**, 4, 395-401		22
127	Copper ions and diamide induce a high affinity guanine-nucleotide-insensitive state for muscarinic agonists. *Biochemical and Biophysical Research Communications*, **1984**, 120, 271-7	3.4	21
126	Altered ontogenesis of muscarinic receptors in agranular cerebellar cortex. *Journal of Neurochemistry*, **1982**, 39, 756-63	6	21
125	Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers. *Drug Development Research*, **2020**, 81, 1073	5.1	21
124	Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. *Pharmacogenomics*, **2013**, 14, 337-9	2.6	20
123	Pharmacogenomics: the importance of accurate phenotypes. *Pharmacogenomics*, **2010**, 11, 469-70	2.6	20
122	CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. *Pharmacogenomics*, **2015**, 16, 689-701	2.6	19
121	Health technology assessment in the era of personalized health care. *International Journal of Technology Assessment in Health Care*, **2011**, 27, 118-26	1.8	19
120	Recognition of the muscarinic receptor by its endogenous neurotransmitter: binding of [3H]acetylcholine and its modulation by transition metal ions and guanine nucleotides. *Proceedings of the National Academy of Sciences of the United States of America*, **1984**, 81, 3650-4	11.5	19
119	Increased agonist affinity is induced in tetranitromethane-modified muscarinic receptors. *Biochemistry*, **1985**, 24, 8086-93	3.2	19
118	RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. *Translational Psychiatry*, **2016**, 6, e909	8.6	19
117	Pharmacogenomic testing: knowing more, doing better. *Clinical Pharmacology and Therapeutics*, **2012**, 91, 387-9	6.1	18
116	TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'?. *Personalized Medicine*, **2009**, 6, 103-113	2.2	18
115	Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. *Pharmacogenomics*, **2007**, 8, 713-9	2.6	18
114	Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. *Life Sciences*, **1996**, 59, 1651-7	6.8	18

113	NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. *NeuroReport*, **1995**, 6, 485-8	1.7	18
112	Ligand-selective signaling and high-content screening for GPCR drugs. *Drug Discovery Today*, **2003**, 8, 1108-9	8.8	17
111	Expression of muscarinic binding sites in primary human brain tumors. *Developmental Brain Research*, **1984**, 316, 61-70		17
110	Gene drives raise dual-use concerns. *Science*, **2014**, 345, 1010	33.3	16
109	Pharmacogenetics education: 10 years of experience at Tel Aviv University. *Pharmacogenomics*, **2010**, 11, 647-9	2.6	16
108	Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders. *Dialogues in Clinical Neuroscience*, **2016**, 18, 267-276	5.7	16
107	MicroRNA-Mediated Regulation of and Is Implicated in SSRI Action. *Frontiers in Molecular Neuroscience*, **2017**, 10, 355	6.1	15
106	Grant application review: the case of transparency. *PLoS Biology*, **2014**, 12, e1002010	9.7	14
105	Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cells. *Annals of the New York Academy of Sciences*, **1995**, 774, 300-3	6.5	14
104	Personalized psychiatry: a realistic goal. *Pharmacogenomics*, **2004**, 5, 213-7	2.6	14
103	Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines. *Genome Medicine*, **2015**, 7, 37	14.4	13
102	Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs. *Journal of Molecular Neuroscience*, **2013**, 49, 554-8	3.3	13
101	Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining. *Drug Development Research*, **2020**, 81, 777-781	5.1	12
100	Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. *Pharmacogenomics*, **2012**, 13, 543-54	2.6	12
99	A gene co-expression module implicating the mitochondrial electron transport chain is associated with long-term response to lithium treatment in bipolar affective disorder. *Translational Psychiatry*, **2018**, 8, 183	8.6	12
98	Do endogenous cannabinoids contribute to HIV-mediated immune failure?. *Trends in Molecular Medicine*, **1998**, 4, 196-200		11
97	Increased KPI containing amyloid precursor protein in experimental autoimmune encephalomyelitis brains. *NeuroReport*, **2007**, 18, 581-4	1.7	11
96	Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. *Translational Psychiatry*, **2016**, 6, e827	8.6	11

95	Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy. *Translational Psychiatry*, **2016**, 6, e950	8.6	10
94	Elevated Cerebrospinal Fluid Glutamate in Patients With HIV-related Dementia. *JAMA - Journal of the American Medical Association*, **1997**, 277, 1931	27.4	10
93	The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns. *Drug Discovery Today*, **2002**, 7, 403-6	8.8	10
92	Novel 5-HT-receptor agonists: F11440, MKC242 and BAYx3702. *Drug Discovery Today*, **1999**, 4, 142-143	8.8	10
91	Rat brain and heart muscarinic receptors: modification with tetranitromethane. *Biochemical and Biophysical Research Communications*, **1985**, 131, 1124-31	3.4	10
90	Progress in medicinal chemistry of novel selective muscarinic agonists. *Drug Design and Discovery*, **1993**, 9, 221-35		10
89	Animal models and human genome diversity: the pitfalls of inbred mice. *Drug Discovery Today*, **2001** , 6, 766-768	8.8	9
88	Characterization of human lymphoblastoid cell lines as a novel in vitro test system to predict the immunotoxicity of xenobiotics. *Toxicology Letters*, **2015**, 233, 8-15	4.4	8
87	Expression profiling: a cost-effective biomarker discovery tool for the personal genome era. *Genome Medicine*, **2013**, 5, 41	14.4	8
86	Genome-wide transcriptomic variations of human lymphoblastoid cell lines: insights from pairwise gene-expression correlations. *Pharmacogenomics*, **2012**, 13, 1893-904	2.6	8
85	Peroxynitrite generation might explain elevated glutamate and aspartate levels in multiple sclerosis cerebrospinal fluid. *European Journal of Clinical Investigation*, **1998**, 28, 760-1	4.6	8
84	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. *Pharmacogenomics*, **2007**, 8, 519	2.6	8
83	Rigid analogs of acetylcholine can be m1-selective agonists: implications for a rational treatment strategy in Alzheimer's disease. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 839-844	2.9	8
82	Protease nexin-1 complexes and inhibits T cell serine proteinase-1. *Biochemical and Biophysical Research Communications*, **1989**, 161, 300-4	3.4	8
81	RNA sequencing of bipolar disorder lymphoblastoid cell lines implicates the neurotrophic factor HRP-3 in lithium's clinical efficacy. *World Journal of Biological Psychiatry*, **2019**, 20, 449-461	3.8	8
80	Peripheral Blood Mononuclear Cell Oxytocin and Vasopressin Receptor Expression Positively Correlates with Social and Behavioral Function in Children with Autism. *Scientific Reports*, **2019**, 9, 13443	4.9	7
79	'Private fears in public places?' Ethical and regulatory concerns regarding human genomic databases. *Personalized Medicine*, **2007**, 4, 447-452	2.2	7
78	Are drug targets missed owing to lack of physical activity?. *Drug Discovery Today*, **2001**, 6, 342-343	8.8	7

77	Genomics and the future of psychopharmacology: MicroRNAs offer novel therapeutics?. *Dialogues in Clinical Neuroscience*, **2019**, 21, 131-148	5.7	7
76	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 313-316	6.1	6
75	N-methyl-citalopram: A quaternary selective serotonin reuptake inhibitor. *Biochemical Pharmacology*, **2010**, 80, 1546-52	6	6
74	Flight attendants, breast cancer, and melatonin. *Lancet, The*, **1998**, 352, 1389-90	40	6
73	Biochemical characterization of the muscarinic receptors. *Advances in Enzymology and Related Areas of Molecular Biology*, **1983**, 55, 137-96		6
72	Ethnic differences of coronary artery disease-associated SNPs in two Israeli healthy populations using MALDI-TOF mass spectrometry. *Life Sciences*, **2004**, 75, 1003-10	6.8	6
71	Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?. *Dialogues in Clinical Neuroscience*, **2018**, 20, 293-300	5.7	6
70	Genetic privacy: trust is not enough. *Science*, **2015**, 347, 957-8	33.3	5
69	Personalized participatory medicine: sharing knowledge and uncertainty. *Genome Medicine*, **2011**, 3, 69	14.4	5
68	Personalized pharmacotherapy: genotypes, biomarkers, and beyond. *Clinical Pharmacology and Therapeutics*, **2009**, 85, 142	6.1	5
67	Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. *Molecular Psychiatry*, **2021**,	15.1	5
66	Cataloging the interactome of small molecules and the human proteome. *Drug Development Research*, **2011**, 72, 1-3	5.1	4
65	Ancestry in translational genomic medicine: handle with care. *Genome Medicine*, **2009**, 1, 24	14.4	4
64	Auguste D and Alzheimer's disease. *Lancet, The*, **1997**, 350, 298	40	4
63	Oestrogen replacement therapy in postmenopausal women. *Lancet, The*, **1999**, 353, 674-5	40	4
62	Estradiol reduces ACE2 and TMPRSS2 mRNA levels in A549 human lung epithelial cells.. *Drug Development Research*, **2022**,	5.1	4
61	COVID-19 vaccine hesitancy: Lessons from Israel. *Vaccine*, **2021**, 39, 3785-3786	4.1	4
60	Recent Selection on a Class I ADH Locus Distinguishes Southwest Asian Populations Including Ashkenazi Jews. *Genes*, **2018**, 9,	4.2	4

59	Selective neurotoxicity induced by the ionophore lasalocid in rat dissociated cerebral cultures, involvement of the NMDA receptor/channel. *NeuroToxicology*, **1996**, 17, 883-95	4.4	4
58	Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health. *Current Pharmacogenomics and Personalized Medicine*, **2011**, 9, 148-155	0.4	3
57	Farm microbiome and childhood asthma. *New England Journal of Medicine*, **2011**, 364, 1972-3; author reply 1973	59.2	3
56	Head circumference and incident Alzheimer's disease: modification by apolipoprotein E. *Neurology*, **2002**, 58, 1440	6.5	3
55	Abnormal potassium-channel function in platelets in Alzheimer's disease. *Lancet, The*, **1999**, 353, 326	40	3
54	Selective neurotoxicity induced by lasalocid in dissociated cerebral cultures. *Toxicology in Vitro*, **1993**, 7, 345-52	3.6	3
53	Physical activity: good for your health, very good for your gene expression. *Clinical Genetics*, **2000**, 57, 249-251	4	3
52	Genetic relationships of Southwest Asian and Mediterranean populations. *Forensic Science International: Genetics*, **2021**, 53, 102528	4.3	3
51	The Alzheimer's disease peptide amyloid promotes thrombin generation through activation of coagulation factor XII: comment. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1488-9	15.4	3
50	Peer review: Award bonus points to motivate reviewers. *Nature*, **2017**, 542, 414	50.4	2
49	RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimer Disease **2017**, 239-251		2
48	Parental consent: Guarding children's genetic privacy. *Nature*, **2013**, 494, 430	50.4	2
47	Serotonin uptake to lymphocytes of patients with social phobia compared to normal individuals. *European Neuropsychopharmacology*, **2006**, 16, 19-23	1.2	2
46	Personalized medicine in psychiatry. *Personalized Medicine*, **2004**, 1, 15-18	2.2	2
45	Profile. *Drug Discovery Today*, **2001**, 6, 1178-1179	8.8	2
44	Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. *Psychoneuroendocrinology*, **2021**, 129, 105234	5	2
43	Selective Signaling Via Novel Muscarinic Agonists: Implications for Alzheimer Disease Treatments and Clinical Update **1994**, 219-223		2
42	New M1 Agonists: Selective Signaling, Neurotrophic-Like and Cognitive Effects Implications in the Treatment of Alzheimer Disease. *Advances in Behavioral Biology*, **1995**, 449-455		2

41	SCN11A mRNA levels in female bipolar disorder PBMCs as tentative biomarker for distinct patient sub-phenotypes. *Drug Development Research*, **2019**, 80, 1128-1135	5.1	1
40	Data re-identification: protect the children. *Science*, **2013**, 339, 1033	33.3	1
39	A deserving role for the National Center for Advancing Translational Sciences. *Lancet, The*, **2011**, 377, 1745-6	40	1
38	Biomarkers: better donor protection. *Nature*, **2011**, 470, 175	50.4	1
37	Response--Biobanks. *Science*, **2009**, 326, 799-799	33.3	1
36	Chorionic villus sampling versus early amniocentesis. *Lancet, The*, **1997**, 350, 1254	40	1
35	Response to Sykiotis and Papavassiliou: Professional education in molecular medicine--pharmacogenetics first. *Trends in Molecular Medicine*, **2005**, 11, 485-6	11.5	1
34	Workshop Abstracts. *Personalized Medicine*, **2005**, 2, 145-185	2.2	1
33	Receptor crosstalk: a surprising twist on an old concept. *Trends in Molecular Medicine*, **2000**, 6, 261		1
32	New imaging techniques for early diagnosis of Alzheimer's disease. *Trends in Neurosciences*, **2000**, 23, 386	13.3	1
31	Fatty acid amide hydrolase inhibitors and the marijuana debate. *Lancet, The*, **2001**, 358, 1548	40	1
30	Complement depletion or blockade could save lives of sepsis victims. *Trends in Molecular Medicine*, **1999**, 5, 376		1
29	AMPA receptors: a better target for ischaemic brain damage?. *Trends in Molecular Medicine*, **1999**, 5, 464		1
28	Molecular cancer target: PI-3-kinase. *Drug Discovery Today*, **1999**, 4, 96	8.8	1
27	The therapeutic potential of nicotine and nicotinic agonists for weight control. *Expert Opinion on Investigational Drugs*, **1999**, 8, 747-60	5.9	1
26	d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cells. *Drug Development Research*, **2021**,	5.1	1
25	Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries. *Vaccine*, **2021**, 39, 1027	4.1	1
24	Telomerase expression and cancer: a controversy finally put to rest?. *Clinical Genetics*, **1999**, 55, 306-8	4	1

23	Conference scene: pharmacogenomics: from cell to clinic (part 2). *Pharmacogenomics*, **2014**, 15, 739-44	2.6	0
22	Genome wide analysis implicates upregulation of proteasome pathway in major depressive disorder. *Translational Psychiatry*, **2021**, 11, 409	8.6	0
21	Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy. *Journal of Psychiatric Research*, **2021**, 141, 92-103	5.2	0
20	Computing: Keep files small to curb energy use. *Nature*, **2014**, 514, 305	50.4	
19	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. *European Neuropsychopharmacology*, **2013**, 23, S168-S169	1.2	
18	A biological basis for the sex bias of antipsychotic drugs adverse events. *Journal of the American Geriatrics Society*, **2013**, 61, 1437	5.6	
17	Personalized Medicine **2007**, 279-295		
16	Workshop Introduction: Personalized medicine: desirable, affordable, attainable?. *Personalized Medicine*, **2005**, 2, 143-144	2.2	
15	Seasonality of birth in patients with type 1 diabetes. *Lancet, The*, **2002**, 359, 1247; author reply 1247-8	40	
14	Renewed hope for medicinal marijuana?. *Trends in Molecular Medicine*, **2000**, 6, 187		
13	New hope for spinal-cord repair from immune activation. *Trends in Molecular Medicine*, **2000**, 6, 415		
12	Cancer therapy: A2B adenosine antagonists for busting tumor angiogenesis?. *Trends in Molecular Medicine*, **2000**, 6, 6		
11	Mast-cell chymase: a new target for anti-inflammatory drugs. *Trends in Molecular Medicine*, **2000**, 6, 99		
10	Sperm conceive cues in surprising ways. *Trends in Molecular Medicine*, **1999**, 5, 8		
9	Coronary artery disease therapy: as as simple as l-arginine?. *Trends in Molecular Medicine*, **1999**, 5, 98		
8	Marihuana and medicine: the debate persists. *Trends in Molecular Medicine*, **1999**, 5, 378		
7	Pharmacogenetic-oriented drug development. *Drug Discovery Today*, **1999**, 4, 151-152	8.8	
6	Beneficial effects of statins. *Lancet, The*, **1996**, 348, 1583	40	

5	Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer's Disease **1997**, 317-322	
4	Human lymphoblastoid cell lines: a valuable tool for personalized medicine research. *Biochemist*, **2016**, 38, 6-9	0.5
3	Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease. *NeuroReport*, **1997**, 8, 1067-8	1.7
2	p53 gene polymorphism and cancer risk: the debate continues. *Clinical Genetics*, **1999**, 55, 305-6	4
1	P.0061 Ketamine affects expression of Itgb3, Itgav, Chl1 and Sirt1 in the prefrontal cortex of rats in a depressive-like behaviour model. *European Neuropsychopharmacology*, **2021**, 53, S44-S45	1.2